Scientific Advisory Board (SAB)

Jean-Marc Vidal Doctor of Medicine (MD)

Jean-Marc Vidal is Doctor of Medicine (MD) pathologist, toxicologist and has a long experience in the regulation of medicines. He worked as a Toxicologist in the Pharmaceutical Industry during over 11 years. He was also Non-clinical Senior Scientific Officer at the European Medicines Agency (EMA) for more than 16 years.

Stephane DHALLUIN, PharmD, PhD, ERT, DABT

Stephane holds a Doctorate of Pharmacy, a PhD in Cellular and Molecular Toxicology from the University of Rouen and an Executive MBA from INSEAD. He is European Registered Toxicologist (ERT) and Diplomate of the American Board of Toxicology (DABT).
He started his career in agrochemical industry (Novartis Crop Protection) in France where he held Toxicologist and Fungicide registration specialist roles. In 2000 he moved to pharmaceutical industry (UCB) in Belgium. He held roles of increasing responsibilities in the latter organization from Toxicologist, Head of Toxicology to Head of Investigative, Chemical and Environmental Safety. Later in his career he was also in charge of creating, developing and leading UCB Alliance Management Centre of Excellence.
He joined L’Oréal in 2015 and is currently heading the Worldwide Safety Evaluation Department whose main global responsibilities are human and environmental safety assessment of ingredients and cosmetic products as well as cosmetovigilance.

Josep V. Castell, MD, PhD. Professor at Faculty of Medicine of the IIS Hospital Universitario La Fe in Valencia

Dr. Castell is the Director of Research at the University Hospital La Fe and Head of the Unit of Experimental Hepatology of the Institute of Health Research of the University Hospital La Fe, of Valencia.

Hennicke Kamp, PhD. Head of Services Experimental Toxicology and Ecology at BASF SE

Hennicke Kamp works at BASF SE since 2010, previously he worked as a Toxicology Consultant for Metanomics GmbH from 2008 to 2010. He holds a PhD in Food Toxicology at the Technical University of Kaiserslautern.

Paul Avillach, MD, PhD. Assistant Professor in Biomedical Informatics and Paediatrics at Harvard Medical School

Paul Avillach  is Assistant Professor of Epidemiology. Department of Epidemiology | Harvard T.H. Chan School of Public Health, and he holds an MD in public health and epidemiology and a PhD in biomedical informatics. Avillach's research focuses on the development of novel methods and techniques for the integration of multiple heterogeneous clinic cohorts, electronic health records data, and multiple types of genomics data to encompass biological observations. He is PI and Co-Investigator on several large projects at the Department of Biomedical Informatics at Harvard Medical School, including the BD2K PIC-SURE Center of Excellence, the Global Rare Diseases Registry project, the PCORI ARCH project, the PCORI Phelan-Mcdermid Syndrome project, NIH Undiagnosed Diseases Network (UDN) coordinating center, NIH Data Commons and NHLBI Data Stage project.

Michael Merz, MD. Scientific Associate at Zurich University Hospital

Dr. Michael Merz is a clinical pharmacologist, with his main focus on drug safety during the past ten years. He worked as phase 1 investigator and Head of Phase 1 clinic for Quintiles and joined Novartis Pharma as Clinical Pharmacology Expert in 1998. At Novartis, he was Head of Modeling and Simulation in Clinical Pharmacology, worked as Senior Medical Safety Expert in Clinical Safety, and led the Systems Toxicology Section in Preclinical Safety. He set up the company’s liver safety expert team in 2008 and has been leading the group until April 2017. Since May 2017, he is working as a scientific associate at Zurich University Hospital, and as a consultant for the pharmaceutical industry, specializing in assessment and management of drug-induced liver injury.

Ethics Advisory Board (EAB)

Magí Farré, MD, PhD. Doctor of Medicine. Head Clinical Pharmacology Unit at Hospital Universitari Germans Trias i Pujol

Magí Farré is Professor of Pharmacology at Universitat Autonoma de Barcelona. He is Member of the Clinical Commission of the National Plan on Drugs from the Spanish Ministry of Health. Dr Farré’s main research area is clinical pharmacology of drug abuse, including novel psychoactive substances. He has experience in clinical trials in healthy subjects and patients, bioethics and methodology of clinical investigation.


Latest News